MA33555B1 - Procédés et compositions pour traiter la leucémie - Google Patents

Procédés et compositions pour traiter la leucémie

Info

Publication number
MA33555B1
MA33555B1 MA34609A MA34609A MA33555B1 MA 33555 B1 MA33555 B1 MA 33555B1 MA 34609 A MA34609 A MA 34609A MA 34609 A MA34609 A MA 34609A MA 33555 B1 MA33555 B1 MA 33555B1
Authority
MA
Morocco
Prior art keywords
compositions
methods
treating leukemia
leukemia
treating
Prior art date
Application number
MA34609A
Other languages
Arabic (ar)
English (en)
Inventor
Mhairi Copland
Marion Dorsch
David Irvine
Paul W Manley
Stefan Peukert
Original Assignee
Univ Glasgow
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Glasgow, Novartis Ag filed Critical Univ Glasgow
Publication of MA33555B1 publication Critical patent/MA33555B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une combinaison d'un inhibiteur de bcr-abl et d'un inhibiteur de voie hedgehog pour le traitement de la leucémie.
MA34609A 2009-08-12 2012-02-07 Procédés et compositions pour traiter la leucémie MA33555B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/539,855 US20110039850A1 (en) 2009-08-12 2009-08-12 Leukemia Treatment
PCT/US2010/045133 WO2011019798A1 (fr) 2009-08-12 2010-08-11 Procédés et compositions pour traiter la leucémie

Publications (1)

Publication Number Publication Date
MA33555B1 true MA33555B1 (fr) 2012-09-01

Family

ID=42727621

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34609A MA33555B1 (fr) 2009-08-12 2012-02-07 Procédés et compositions pour traiter la leucémie

Country Status (19)

Country Link
US (3) US20110039850A1 (fr)
EP (1) EP2464423A1 (fr)
JP (1) JP2013501798A (fr)
KR (1) KR20120089844A (fr)
CN (2) CN103736094A (fr)
AU (1) AU2010282547A1 (fr)
BR (1) BR112012003278A2 (fr)
CA (1) CA2769300A1 (fr)
CL (1) CL2012000350A1 (fr)
IL (1) IL217764A0 (fr)
MA (1) MA33555B1 (fr)
MX (1) MX2012001846A (fr)
NZ (1) NZ597864A (fr)
PH (1) PH12014500538A1 (fr)
RU (1) RU2012108930A (fr)
SG (2) SG178082A1 (fr)
TN (1) TN2012000029A1 (fr)
WO (1) WO2011019798A1 (fr)
ZA (1) ZA201200434B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104262262B (zh) * 2014-08-29 2016-06-08 西安交通大学 一种N,6二苯基嘧啶-4-胺类Bcr-Abl抑制剂及其制备方法和应用
US10800757B2 (en) 2017-10-27 2020-10-13 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
TWI904875B (zh) * 2023-09-28 2025-11-11 大陸商深圳市塔吉瑞生物醫藥有限公司 雜稠環化合物及其組合物及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
BRPI0809193A2 (pt) * 2007-03-15 2014-09-23 Novartis Ag Compostos orgânicos e seus usos
ES2569941T3 (es) * 2007-06-07 2016-05-13 Novartis Ag Derivados de bifenilcarboxamida como moduladores de la ruta de hedgehog
JP2010536775A (ja) * 2007-08-16 2010-12-02 アイアールエム・リミテッド・ライアビリティ・カンパニー 癌を処置するための方法および組成物
WO2010030948A2 (fr) * 2008-09-12 2010-03-18 The Board Of Trustees Of The Leland Stanford Junior University Signalisation hedgehog et cellules souches cancéreuses dans des malignités de cellules hématopoïétiques

Also Published As

Publication number Publication date
ZA201200434B (en) 2012-10-31
RU2012108930A (ru) 2013-09-20
CN103736094A (zh) 2014-04-23
US20120329798A1 (en) 2012-12-27
KR20120089844A (ko) 2012-08-14
PH12014500538A1 (en) 2015-09-07
JP2013501798A (ja) 2013-01-17
CA2769300A1 (fr) 2011-02-17
WO2011019798A1 (fr) 2011-02-17
NZ597864A (en) 2014-01-31
TN2012000029A1 (en) 2013-09-19
EP2464423A1 (fr) 2012-06-20
CL2012000350A1 (es) 2012-10-12
BR112012003278A2 (pt) 2016-03-01
AU2010282547A1 (en) 2012-02-16
SG10201407435WA (en) 2014-12-30
CN102695547A (zh) 2012-09-26
US20150209365A1 (en) 2015-07-30
IL217764A0 (en) 2012-03-29
MX2012001846A (es) 2012-05-22
SG178082A1 (en) 2012-03-29
US20110039850A1 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
FR23C1003I2 (fr) Compositions et leurs utilisations pour le traitement de la Sclérose en plaques
EP2224955A4 (fr) Compositions et procédés pour la prévention et le traitement de l'arthrite
MA35210B1 (fr) Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EP2429574A4 (fr) Compositions et methodes de traitement des cancers hematologiques, ciblant l'interaction sirp -cd47
FR2932478B1 (fr) Composes utiles pour le traitement des cancers.
EP2182804A4 (fr) Procédés de traitement d'une dépendance
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
EP2109687A4 (fr) Méthodes et compositions utilisant des micro-arn pour le traitement de la leucémie aigüe myéloïde (lam)
EP1996182A4 (fr) Traitement anticancéreux utilisant des inhibiteurs de gamma-sécrétases
MA32748B1 (fr) Traitement du cancer de l'utérus du cancer de l'ovaire avec un inhibiteur parp utilisé seul ou en combinaison avec des antitumoraux
EP2569434A4 (fr) Compositions et méthodes de traitement de la leucémie
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
EP2063882A4 (fr) Inhibiteurs de kinase pour la prévention ou le traitement d'une infection
EP2554175A4 (fr) Composition pour le traitement d'une partie lésée
EP1996612A4 (fr) Compositions destinee au traitement des cancers
EP2338519A4 (fr) Agent de traitement d'une myélofibrose
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201170832A1 (ru) Пуриновые соединения
EP2393785A4 (fr) 1,1,3,3-tétraoxydobenzo[d][1,3,2]dithiazoles substitués en tant que potentialisateurs allostériques de mglur4, compositions et procédés de traitement d'un dysfonctionnement neurologique
MA33739B1 (fr) Procédés et compositions pour traiter des tumeurs solides et d'autres malignités
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
EP2249789A4 (fr) Compositions et méthodes pour le traitement de la xérostomie